Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS)
Public ClinicalTrials.gov record NCT00413114. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Obatoclax Mesylate (GX15-070MS) in Patients With Previously-Untreated Myelodysplastic Syndromes (MDS) With Anemia and/or Thrombocytopenia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogeneic signal is present. Obatoclax is designed to restore apoptosis through inhibition of the Bcl-2 family of proteins, thereby reinstating the natural process of cell death that is often inhibited in cancer cells. This is a multi-center, open-label, Phase II study of obatoclax administered in 2-week cycles to patients with previously-untreated Myelodysplastic Syndromes with anemia and/or thrombocytopenia. Treatment may be administered on an outpatient basis. No investigational or commercial agents or therapies other than those described herein may be administered with the intent to treat the patient's malignancy. Supportive care measures including those directed at controlling symptoms resulting from Myelodysplastic Syndromes are allowed
Study identification
- NCT ID
- NCT00413114
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 24 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2006 (Type not available)
- Primary completion
- Feb 2009 (Actual)
- Completion
- Nov 2009 (Actual)
- Last update posted
- Aug 26, 2013
2006 – 2009
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University | Stanford | California | 00000 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| James A. Haley Veterans Hospital | Tampa | Florida | 33612 | — |
| Emory University School of Medicine/ Winship Cancer Center | Atlanta | Georgia | 30322 | — |
| Northwest Georgia Oncology Centers | Marietta | Georgia | 30060 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| University of Massachusetts Medical Center | Worcester | Massachusetts | 01605 | — |
| Michigan State University, Breslin Cancer Center CTO | Lansing | Michigan | 48910 | — |
| Hematology-Oncology Centers of the Northern Rockies | Billings | Montana | 59101 | — |
| St. Vincent's Comprehensive Cancer Center | New York | New York | 01605 | — |
| Pacific Oncology | Portland | Oregon | 97210 | — |
| The West Clinic | Memphis | Tennessee | 38120 | — |
| Sarah Cannon Cancer Research Institute | Nashville | Tennessee | 37203 | — |
| Arlington Cancer Center | Arlington | Texas | 76012 | — |
| Texax Oncology, P.A., Presbyterian/ Mary Crowley Clinical Research Centers | Dallas | Texas | 75231 | — |
| Mary Crowley Medical Research Center | Dallas | Texas | 75246 | — |
| MD Anderson Cancer Center (Protocol 2006-0688) | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00413114, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 26, 2013 · Synced Nov 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00413114 live on ClinicalTrials.gov.